{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:02:20Z","timestamp":1789628540252,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10620-026-10188-1","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T18:40:51Z","timestamp":1787078451000},"page":"5939-5947","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Higher Off-Therapy Relapse Risk with Tenofovir Alafenamide than Entecavir in Non-cirrhotic HBeAg-Negative Chronic Hepatitis B: Insights from End-of-Treatment qHBsAg Stratification"],"prefix":"10.1007","volume":"71","author":[{"given":"Yi-Jie","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou-Wu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Fang","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Chia","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Yu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Chun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0887-6432","authenticated-orcid":false,"given":"Jun-Sing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"10188_CR1","unstructured":"World Health Organization. Hepatitis B. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b (accessed 6 February 2026)."},{"key":"10188_CR2","first-page":"204993612098595","volume":"8","author":"L Roade","year":"2021","unstructured":"Roade L, Riveiro-Barciela M, Esteban R et al. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis 2021;8:2049936120985954.","journal-title":"Ther Adv Infect Dis"},{"key":"10188_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1\u201398.","journal-title":"Hepatol Int"},{"key":"10188_CR4","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2025; 83: 502\u201383.","DOI":"10.1016\/j.jhep.2025.03.018"},{"key":"10188_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","volume":"15","author":"JH Kao","year":"2021","unstructured":"Kao JH, Jeng WJ, Ning Q et al. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833\u2013851.","journal-title":"Hepatol Int"},{"key":"10188_CR6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/apt.17105","volume":"56","author":"J Lok","year":"2022","unstructured":"Lok J, Dusheiko G, Carey I et al. Review article: novel biomarkers in hepatitis B infection. Aliment Pharmacol Ther 2022;56:760\u2013776.","journal-title":"Aliment Pharmacol Ther"},{"key":"10188_CR7","doi-asserted-by":"crossref","unstructured":"Hadziyannis E, Laras A. Viral Biomarkers in Chronic HBeAg Negative HBV Infection. Genes (Basel) 2018; 9","DOI":"10.3390\/genes9100469"},{"key":"10188_CR8","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","volume":"13","author":"CH Chen","year":"2015","unstructured":"Chen CH, Hung CH, Hu TH et al. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol 2015;13:1984\u201392.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10188_CR9","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1016\/j.cgh.2020.04.037","volume":"18","author":"TN Tseng","year":"2020","unstructured":"Tseng TN, Hu TH, Wang JH et al. Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU\/mL. Clin Gastroenterol Hepatol 2020;18:2803\u201312.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10188_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3350\/cmh.2016.0047","volume":"22","author":"HA Lee","year":"2016","unstructured":"Lee HA, Seo YS, Park SW et al. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B. Clin Mol Hepatol 2016;22:382\u2013389.","journal-title":"Clin Mol Hepatol"},{"key":"10188_CR11","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 2006;43:1317\u20131325.","journal-title":"Hepatology"},{"key":"10188_CR12","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/j.cgh.2016.07.002","volume":"14","author":"WJ Jeng","year":"2016","unstructured":"Jeng WJ, Chen YC, Sheen IS et al. Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients. Clin Gastroenterol Hepatol 2016;14:1813\u201320.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10188_CR13","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.14309\/ajg.0000000000003324","volume":"120","author":"HW Fang","year":"2025","unstructured":"Fang HW, Jeng WJ, Hu TH et al. Higher Relapse Rate in HBeAg-Negative Patients After Cessation of Tenofovir Alafenamide Compared With Entecavir or Tenofovir Disoproxil Fumarate. Am J Gastroenterol 2025;120:2567\u20132575.","journal-title":"Am J Gastroenterol"},{"key":"10188_CR14","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1111\/jgh.16923","volume":"40","author":"CH Tseng","year":"2025","unstructured":"Tseng CH, Lee TY, Chen CY et al. Incidences of Virological and Clinical Relapses After Cessation of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Entecavir in Patients With HBeAg-Negative Chronic Hepatitis B. J Gastroenterol Hepatol 2025;40:1245\u20131254.","journal-title":"J Gastroenterol Hepatol"},{"key":"10188_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.dld.2023.01.154","volume":"55","author":"CH Chen","year":"2023","unstructured":"Chen CH, Jeng WJ, Hu TH et al. HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate with or without switching to tenofovir alafenamide. Dig Liver Dis 2023;55:771\u2013777.","journal-title":"Dig Liver Dis"},{"key":"10188_CR16","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.jhep.2020.11.043","volume":"74","author":"M Garc\u00eda-L\u00f3pez","year":"2021","unstructured":"Garc\u00eda-L\u00f3pez M, Lens S, Pallett LJ et al. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. J Hepatol 2021;74:1064\u20131074.","journal-title":"J Hepatol"},{"key":"10188_CR17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","volume":"67","author":"K Murata","year":"2018","unstructured":"Murata K, Asano M, Matsumoto A et al. Induction of IFN-\u03bb3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut 2018;67:362\u2013371.","journal-title":"Gut"},{"key":"10188_CR18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1159\/000544870","volume":"43","author":"YJ Huang","year":"2025","unstructured":"Huang YJ, Lee SW, Tung CF et al. HBV Relapse after Discontiniuation of Tenofovir Alafenamide or Entecavir in Non-Cirrhotic Hepatitis B e Antigen-Negative Patients. Dig Dis 2025;43:336\u2013344.","journal-title":"Dig Dis"},{"key":"10188_CR19","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1016\/j.cgh.2020.04.048","volume":"18","author":"SM Chiu","year":"2020","unstructured":"Chiu SM, Kuo YH, Wang JH et al. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy. Clin Gastroenterol Hepatol 2020;18:2989\u201397.e3.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10188_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s12072-021-10159-w","volume":"15","author":"YH Kuo","year":"2021","unstructured":"Kuo YH, Wang JH, Hung CH et al. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation. Hepatol Int 2021;15:301\u2013309.","journal-title":"Hepatol Int"},{"key":"10188_CR21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/jvh.13528","volume":"28","author":"PY Huang","year":"2021","unstructured":"Huang PY, Wang JH, Hung CH et al. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients. J Viral Hepat 2021;28:1141\u20131149.","journal-title":"J Viral Hepat"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10188-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-10188-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10188-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:07:25Z","timestamp":1789625245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-10188-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10188"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-10188-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"5 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that there are no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved by the Institutional Review Board (IRB) of Taichung Veterans General Hospital (IRB number: CE-25759A). The study has been granted an exemption from requiring written informed consent by the same IRB\n                      .","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}